$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000162828023027818 Filed on August 07, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$13.00M	$13.24M
YoY Change	13.43%	-0.18%
Cost Of Revenue	$4.798M	$6.617M
YoY Change	3.74%	26.23%
Gross Profit	$8.204M	$6.624M
YoY Change	19.98%	-17.44%
Gross Profit Margin	63.1%	50.03%
Selling, General & Admin	$7.385M	$7.360M
YoY Change	-40.73%	-52.78%
% of Gross Profit	90.02%	111.11%
Research & Development	$3.196M	$3.473M
YoY Change	-1.11%	-33.19%
% of Gross Profit	38.96%	52.43%
Depreciation & Amortization	$218.0K	$250.0K
YoY Change	-60.86%	-61.83%
% of Gross Profit	2.66%	3.77%
Operating Expenses	$10.58M	$10.83M
YoY Change	-32.57%	-47.88%
Operating Profit	-$2.377M	-$4.209M
YoY Change	-73.15%	-67.02%
Interest Expense	$1.256M	$1.373M
YoY Change	-23.83%	-16.02%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.175M	-$5.508M
YoY Change	-82.65%	-66.21%
Income Tax	-$140.0K	$284.0K
% Of Pretax Income
Net Earnings	-$2.035M	-$5.792M
YoY Change	-83.77%	-64.47%
Net Earnings / Revenue	-15.65%	-43.74%
Basic Earnings Per Share	-$0.03	-$0.10
Diluted Earnings Per Share	-$0.03	-$0.10
COMMON SHARES
Basic Shares Outstanding	61.73B shares	55.92M shares
Diluted Shares Outstanding	64.68M shares	57.35M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.92M	$22.44M
YoY Change	33.63%	26.79%
Cash & Equivalents	$24.92M	$22.44M
Short-Term Investments
Other Short-Term Assets	$1.910M	$1.301M
YoY Change	-3.34%	-20.53%
Inventory	$7.079M	$5.950M
Prepaid Expenses
Receivables	$8.550M	$10.10M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$42.46M	$39.79M
YoY Change	11.47%	-8.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.551M	$4.602M
YoY Change	6.23%	0.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.454M	$5.469M
YoY Change	-7.45%	-7.26%
Total Long-Term Assets	$16.99M	$17.21M
YoY Change	23.5%	34.37%
TOTAL ASSETS
Total Short-Term Assets	$42.46M	$39.79M
Total Long-Term Assets	$16.99M	$17.21M
Total Assets	$59.45M	$56.99M
YoY Change	14.66%	1.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.994M	$10.69M
YoY Change	-9.74%	20.28%
Accrued Expenses	$5.468M	$4.263M
YoY Change	-29.29%	-39.46%
Deferred Revenue	$2.637M	$3.992M
YoY Change	240.7%	149.66%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.610M	$18.36M
YoY Change	-67.59%	88.33%
Total Short-Term Liabilities	$24.06M	$38.65M
YoY Change	-34.2%	30.43%
LONG-TERM LIABILITIES
Long-Term Debt	$34.56M	$20.80M
YoY Change	-10.64%	-52.53%
Other Long-Term Liabilities	$2.011M	$2.006M
YoY Change	-6.86%	-15.68%
Total Long-Term Liabilities	$2.011M	$2.006M
YoY Change	-6.86%	-15.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.06M	$38.65M
Total Long-Term Liabilities	$2.011M	$2.006M
Total Liabilities	$162.4M	$163.6M
YoY Change	1.7%	7.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$311.0M	-$308.9M
YoY Change	4.05%	7.9%
Common Stock	$67.00K	$62.00K
YoY Change	24.07%	16.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$102.9M	-$106.7M
YoY Change
Total Liabilities & Shareholders Equity	$59.45M	$56.99M
YoY Change	14.66%	1.21%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.035M	-$5.792M
YoY Change	-83.77%	-64.47%
Depreciation, Depletion And Amortization	$218.0K	$250.0K
YoY Change	-60.86%	-61.83%
Cash From Operating Activities	-$2.350M	-$7.907M
YoY Change	-183.66%	20.5%
INVESTING ACTIVITIES
Capital Expenditures	$150.0K	$826.0K
YoY Change	-108.74%	-222.01%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$150.0K	-$826.0K
YoY Change	-91.26%	22.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.980M	4.287M
YoY Change	-3708.7%	-57.96%
NET CHANGE
Cash From Operating Activities	-2.350M	-7.907M
Cash From Investing Activities	-150.0K	-826.0K
Cash From Financing Activities	4.980M	4.287M
Net Change In Cash	2.480M	-4.446M
YoY Change	159.96%	-250.25%
FREE CASH FLOW
Cash From Operating Activities	-$2.350M	-$7.907M
Capital Expenditures	$150.0K	$826.0K
Free Cash Flow	-$2.500M	-$8.733M
YoY Change	-155.24%	48.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61615959	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	913000	usd
CY2022Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-93143000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	15000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2219000	usd
CY2022Q2	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-96357000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2276000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29522000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	614000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1394000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	975000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3132000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	115000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	109000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	3722000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	267000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	161000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	4728000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	6949000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	170000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	970000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1812000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2446000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	743000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	574000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4643000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2021000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4182000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7202000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	909000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21044000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	828000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	781000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-828000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-781000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5090000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2473000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3805000	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	3542000	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	5878000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	31000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	15000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	12543000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1027000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	675000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4918000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11496000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4837000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10329000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22436000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17695000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2820000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3219000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3542000	usd
CY2023Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2172000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22436000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308931000	usd
CY2023Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2172000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2139000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	37112000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32930000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13241000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13241000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13265000	usd
CY2023Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	7969000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	3274000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023Q2	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	0	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	669000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	0	usd
	aqst	Accounts Receivable Allowances Reclassifications AccountsReceivableAllowancesReclassifications	582000	usd
CY2023Q2	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	0	usd
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	0	usd
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	0	usd
CY2023Q2	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	636000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1012000	usd
CY2022Q2	aqst	Pro Rata Portion Of Target Bonus ProRataPortionOfTargetBonus	280000	usd
CY2022Q2	aqst	Cash Payment Representing90 Days Of Base Pay CashPaymentRepresenting90DaysOfBasePay	150000	usd
CY2022Q2	aqst	Days Of Base Pay DaysOfBasePay	90	d
CY2022Q2	us-gaap	Severance Costs1 SeveranceCosts1	263000	usd
CY2022Q2	aqst	Number Of Installments NumberOfInstallments	3	installment
CY2022Q2	aqst	Severance Period SeverancePeriod	P18M
CY2022Q2	aqst	Coverage Duration CoverageDuration	P18M
CY2022Q2	aqst	Consulting Fee ConsultingFee	10000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	223000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1504000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1899000	usd
CY2023Q2	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	3321000	usd
CY2022Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	2914000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1125000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	967000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	5950000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5780000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47101000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46048000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42499000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41963000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4602000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4085000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	250000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	655000	usd
	us-gaap	Depreciation Depreciation	536000	usd
	us-gaap	Depreciation Depreciation	1369000	usd
CY2023Q2	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	452000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	870000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	121000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	229000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	424000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	843000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	127000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	603000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1230000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1266000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1300000	usd
CY2023Q2	aqst	Lessee Operating Lease Liability To Be Paid Year Four And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter	6318000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10717000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4760000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5957000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3010000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2932000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1357000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1435000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	78000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	78000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	156000	usd
CY2023Q2	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	4000000	usd
CY2022Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	5000000	usd
CY2023Q2	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1469000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1451000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5469000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6451000	usd
CY2023Q2	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	royalty_payment
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2800000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6389000	usd
CY2023Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	299000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	322000	usd
CY2023Q2	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	636000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1012000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	528000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	244000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4263000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7967000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	usd
	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	9171000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	19487000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10317000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	38975000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	38975000	usd
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3542000	usd
CY2022Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65259000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	107000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
CY2023Q2	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1000000	usd
CY2023Q2	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64455000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5792000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2276000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29522000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57350902	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45462516	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56494805	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43475198	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57350902	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45462516	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58938222	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43475198	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	648000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2221000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	992000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3134000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	648000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2221000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	992000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3134000	usd
CY2022Q4	us-gaap	Share Price SharePrice	1.65
	aqst	Inducement Equity Common Stock Options Outstanding Shares InducementEquityCommonStockOptionsOutstandingShares	0	shares
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.052
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.111
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	284000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	284000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5508000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2560000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29522000	usd

Files In Submission

Name	View Source	Status
0001628280-23-027818-index-headers.html	Edgar Link	pending
0001628280-23-027818-index.html	Edgar Link	pending
0001628280-23-027818.txt	Edgar Link	pending
0001628280-23-027818-xbrl.zip	Edgar Link	pending
aqst-06302023ex311.htm	Edgar Link	pending
aqst-06302023ex312.htm	Edgar Link	pending
aqst-06302023ex321.htm	Edgar Link	pending
aqst-06302023ex322.htm	Edgar Link	pending
aqst-20230630.htm	Edgar Link	pending
aqst-20230630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
aqst-20230630_def.xml	Edgar Link	unprocessable
aqst-20230630_lab.xml	Edgar Link	unprocessable
aqst-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aqst-20230630_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aqst-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2023 Q3 Form 10-Q Financial Statement

#000162828023027818 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2023 Q3 Form 10-Q Financial Statement

#000162828023027818 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst